$BIIB News

Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S. For Initiation Therapy For Early Alzheimer’s Disease

Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?

What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

Is Wall Street Bullish or Bearish on Biogen Stock?

Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating

Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target

Biogen (BIIB) Q2 2026 Earnings Call Transcript

Biogen Completes Acquisition of RayThera Inc.

Mizuho Maintains Outperform on Biogen, Raises Price Target to $241

Citigroup Maintains Neutral on Biogen, Raises Price Target to $215

BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook

UBS Maintains Buy on Biogen, Raises Price Target to $240

HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251

Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240

Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248

TD Cowen Maintains Buy on Biogen, Raises Price Target to $225

Wedbush Maintains Neutral on Biogen, Raises Price Target to $215

Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?